

R&D Pipeline Phase III & Registration

Phase III

| Name | Description | Indication |
|--|---|---|
| Dupixent ^{®A} | Anti-IL-4/IL-13 mAb | Bullous Pemphigoid |
| Dupixent ^{®A} | Anti-IL-4/IL-13 mAb | Chronic Spontaneous Urticaria |
| Dupixent ^{®A} | Anti-IL-4/IL-13 mAb | Chronic Obstructive Pulmonary Disease |
| Dupixent ^{®A} | Anti-IL-4/IL-13 mAb | Chronic Inducible Cold Urticaria |
| Dupixent ^{®A} | Anti-IL-4/IL-13 mAb | Chronic Rhinosinusitis without Nasal Polyps |
| Dupixent ^{®A} | Anti-IL-4/IL-13 mAb | Allergic Fungal Rhinosinusitis |
| Dupixent ^{®A} | Anti-IL-4/IL-13 mAb | Chronic Pruritus of Unknown Origin |
| itepekimab ^A | Anti-IL-33 mAb | Chronic Obstructive Pulmonary Disease |
| Sarclisa [®] | Anti-CD38 mAb + combinations | 1L Newly Diag. MM T1 (IMROZ) |
| Sarclisa [®] | Anti-CD38 mAb + combinations | 1L Newly Diag. MM T2 (GMMG) |
| Sarclisa [®] | Anti-CD38 mAb + combinations | Smoldering MM (ITHACA) |
| amcenestrant | SERD + palbociclib | 1L Metastatic breast cancer |
| amcenestrant | SERD | Adjuvant breast cancer |
| tusamitamab ravtansine | Anti-CEACAM5 ADC | 2/3L NSCLC |
| tolebrutinib | BTK inhibitor | Relapsing Multiple Sclerosis |
| tolebrutinib | BTK inhibitor | Primary Progressive MS |
| tolebrutinib | BTK inhibitor | Secondary Progressive MS |
| tolebrutinib | BTK inhibitor | Myasthenia Gravis |
| Nexviazyme [®] | Enzyme Replacement Therapy (GAA) | Pompe Disease - Infantile Onset |
| venglustat | Oral GCS inhibitor | GM2 Gangliosidosis |
| venglustat | Oral GCS inhibitor | Gaucher Disease Type 3 |
| venglustat | Oral GCS inhibitor | Fabry Disease |
| fitusiran | RNAi targeting anti-thrombin | Hemophilia A and B |
| fitusiran | RNAi targeting anti-thrombin | Hemophilia A and B pediatric |
| rilzabrutinib | BTK inhibitor | Immune Thrombocytopenia |
| efanesoctocog alfa ^B | rFVIIIIFc – vWF – XTEN | Hemophilia A |
| MenQuadfi [®] | Meningococcal (A,C,Y,W) conjugate vaccine | Meningitis 6w+ (U.S. / EU) |
| VRVg | Purified vero rabies vaccine | Rabies |

Registration

| Name | Description | Indication |
|--------------------------------|---------------------------------|-----------------------------------|
| Dupixent ^{®A} | Anti-IL-4/IL-13 mAb | Prurigo Nodularis |
| Libtayo ^{®A} | Anti-PD-1 mAb + chemotherapy | 1L NSCLC |
| SP0253 ^D | Recombinant baculovirus Vaccine | COVID-19 |
| nirsevimab ^C | Anti-RSV mAb | Respiratory Syncytial Virus (RSV) |

- Immuno-inflammation
- Oncology
- Neurology
- Rare Diseases
- Rare Blood Disorders
- Vaccines

R&D Pipeline – Phase II

Phase II

| | Name | Description | Indication |
|---|------------------------------------|----------------------------------|---|
| R | Kevzara ^{®A} | Anti-IL-6 mAb | Polyarticular Juvenile Idiopathic Arthritis |
| R | Kevzara ^{®A} | Anti-IL-6 mAb | Systemic Juvenile Arthritis |
| | amlitelimab ¹ | Anti-OX40L mAb | Atopic Dermatitis |
| | rilzabrutinib | BTK inhibitor | IgG4-related disease |
| | rilzabrutinib | BTK inhibitor | Atopic Dermatitis |
| | rilzabrutinib | BTK inhibitor | Asthma |
| | rilzabrutinib | BTK inhibitor | Chronic Spontaneous Urticaria |
| | eclitasertib ^{E,2} | RIPK1 inhibitor | Cutaneous Lupus Erythematosus |
| | SAR441344 ^F | Anti-CD40L mAb | Sjogren's Syndrome |
| | SAR441344 ^F | Anti-CD40L mAb | Systemic Lupus Erythematosus |
| | SAR444727 | BTK inhibitor (topical) | Atopic Dermatitis |
| | SAR445088 ³ | Complement C1s inhibitor | Antibody-Mediated Rejection |
| R | Sarclisa [®] | Anti-CD38 mAb | 1-2L AML / ALL pediatrics |
| | Sarclisa [®] | Anti-CD38 mAb + combinations | Relapsed, Refractory Multiple Myeloma |
| | alomfilimab ⁴ | Anti-ICOS mAb | Solid tumors |
| | tusamitamab ravtansine | Anti-CEACAM5 ADC + ramucirumab | 2/3L NSCLC |
| | tusamitamab ravtansine | Anti-CEACAM5 ADC | Exploratory Solid tumors |
| | tusamitamab ravtansine | Anti-CEACAM5 ADC + pembrolizumab | 1L NSCLC |
| | tusamitamab ravtansine | Anti-CEACAM5 ADC + ramucirumab | Gastric cancer |
| | SAR444245 ⁵ | Non-alpha IL-2 + cemiplimab | Skin cancers |
| | SAR444245 ⁵ | Non-alpha IL-2 + combinations | Gastrointestinal cancer |
| | SAR444245 ⁵ | Non-alpha IL-2 + combinations | NSCLC / Mesothelioma |
| | SAR444245 ⁵ | Non-alpha IL-2 + combinations | Head & Neck tumors |
| | SAR444245 ⁵ | Non-alpha IL-2 + combinations | Lymphoma |
| | SAR442720 ^G | SHP2 inhibitor + KRAS inhibitor | 2L NSCLC |

| | Name | Description | Indication |
|--|--|-------------------------------------|---------------------------------------|
| | SAR445088 ³ | Complement C1s inhibitor | CIDP |
| | SAR441344 ^F | Anti-CD40L mAb | Multiple Sclerosis |
| | SAR443820 ^{E,6} | RIPK1 inhibitor | Amyotrophic Lateral Sclerosis |
| | Sarclisa [®] | Anti-CD38 mAb | Warm Autoimmune Hemolytic Anemia |
| | rilzabrutinib | BTK inhibitor | Warm Autoimmune Hemolytic Anemia |
| | SAR445088 ³ | Complement C1s inhibitor | Cold Agglutinin Disease |
| | Fluzone [®] HD (SP0178) | Inactivated influenza Vaccine (IIV) | Pediatric Flu |
| | SP0218 | Vero cell Vaccine | Yellow fever |
| | SP0202 ^H | Next Generation Conjugate Vaccine | Pneumococcal |
| | SP0125 | Live Attenuated Virus Vaccine | Respiratory syncytial virus (toddler) |
| | SP0230 | Multicomponent Vaccine | Meningitis B |

- Immuno-inflammation
- Oncology
- Neurology
- Rare Diseases
- Rare Blood Disorders
- Vaccines
- R Registrational Study (other than Phase 3)

As of June 30, 2022. For collaborations see slide 55. For abbreviations see slide 56.
 1. Formerly known as SAR445229/KY1005. 2. Also known as SAR443122/DNL758.

3. Formerly known as BIVV020.

4. Formerly known as KY1044/SAR445256.

5. Formerly known as THOR707.

6. Also known as DNL788. Planned to enter phase 2 in MS.

R&D Pipeline – Phase I

Phase I

| Name | Description | Indication |
|--------------------------------|------------------------------------|--------------------------|
| SAR441566 | Oral TNF inhibitor | Inflammatory indications |
| SAR444656^{I,1} | IRAK4 degrader | Atopic Dermatitis |
| SAR444336 | Pegylated IL-2 | Inflammatory Indication |
| SAR443726 | Anti-IL-13/OX40L Nanobody® VHH | Atopic Dermatitis |
| SAR442970 | Anti-TNFα/OX40L Nanobody® VHH | Inflammatory Indication |
| SAR443765 | Anti-IL-13/TSLP Nanobody® VHH | Inflammatory Indication |
| SAR442999 | Anti-TNFα/IL-23A Nanobody® VHH | Inflammatory Indication |
| SAR441000^J | Cytokine mRNA | Solid tumors |
| SAR442257 | Anti-CD38/CD28/CD3 trispecific mAb | MM / N-H Lymphoma |
| SAR442720^G | SHP2 inhibitor + pembrolizumab | 1L NSCLC |
| SAR444881^K | Anti-ILT2 mAb | Solid tumors |
| SAR445419³ | NK-cell-based immunotherapy | Acute Myeloid Leukemia |
| SAR443216 | Anti-CD3/CD28/HER2 trispecific mAb | Gastric cancer |
| SAR445710⁴ | Anti-PD-L1/IL-15 fusion protein | Solid tumors |
| SAR443579^L | Anti-NKp46/CD123 bispecific mAb | Acute Myeloid Leukemia |
| SAR446309⁵ | HER2 T-Cell engager | Solid tumors |
| SAR442501 | Anti-FGFR3 Ab | Achondroplasia |
| SAR443809 | Anti-Factor Bb mAb | Rare renal diseases |
| SP0273 | mRNA Vaccine | Influenza |

- Immuno-inflammation
- Oncology
- Neurology
- Rare Diseases
- Rare Blood Disorders
- Vaccines

As of June 30, 2022. For collaborations see slide 55. For abbreviations see slide 56.

1. Also known as KT474. 2. Also known as SAR443122/DNL758. 3. Formerly known as KDS1001. 4. Formerly known as KD033. 5. Formerly known as AMX-818.